Renin-angiotensin axis blockers in combination hypertension therapy
Authors:
M. Souček
Authors place of work:
II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
Category:
Online
Summary
Current hypertension therapy is still not achieving the target blood pressure values. Combination therapy should be used instead of monotherapy, as monothery normalizes blood pressure in only about 20% of patients. Recent clinical trials have shown that combining an angiotensin-converting enzyme inhibitor (ACEI) with a calcium channel blocker (CCB) provides better results with respect to the incidence of cardiovascular events than a combination of a diuretic and ACEI. Renin-angiotensin axis blocking combination therapy: an ACEI with a CCB, an ACEI with a diuretic or an angiotensin receptor (AT1) blocker with a diuretic as the first line treatment of hypertension stage II might provide significantly better control of blood pressure than monotherapy.
Key words:
combination therapy – angiotensin-converting enzyme inhibitors – angiotensin receptor blockers – diuretics – calcium channel blockers
Zdroje
1. Patel A, ADVANCE Collaborating Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular aoutcomes in patients type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–840.
2. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–1898.
3. Jamerson K, Bakris GL, Dahlöf B et al. ACCOMPLISH Investigators. Exceptional early blood pressure control rates: The ACCOPMLISH trial. Blood Pressure 2007; 16: 80–86.
4. Weir MR, Neutel JM, Bhaumik A et al. The efficacy and safety of initial use of irbesartan/HCTZ fixed dose combination in hypertensive patients with a without high cardiovascular risk. J Clin Hypertens 2007; 9 (12 Suppl): 23–30.
5. Neutel JM, Franklin SS, Lapuerta P et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008; 22: 266–274.
6. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. INVEST investigators. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with corononary heart disease: The International Verapamil-Trandolapril Study (INVEST): A randomised controlled trial. JAMA 2003; 290: 2805–2816.
7. Nadar S, Lim HS, Beevers DG et al. Lipid lowering in hypertension and heart protection: observation from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. J Hum Hypertens 2002; 16: 815–817.
8. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
9. Weber MA. New opportunities in cardiovascular patient management: A survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol 2007; 100: 45J–52J.
10. Doulton TW, He FJ, MacGregor GA. Systemic review of combined angiotensin--converting enzyme inhibitor and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880–886.
11. Sleight P. The ONTARGET/TRANSCEND trial program: baseline data. Acta Diabetol 2005; 42 (Suppl 1): S50–S56.
12. Fischer ND, Hollenberg NK. Renin inhibition: What are the therapeutic opportunities? J Am Soc Nephrol 2005; 16: 592–599.
13. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 2007; 370: 221–229.
14. Messerli FH, Bell DS, Fonesca V et al. GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med 2007; 120: 610–615.
15. Bakris GL, Fonseca V, Katholi RE et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227–2236.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
Najčítanejšie tento týždeňNajčítanejšie v tomto čísle
- Antibiotic treatment of acute bacterial infections
- Management of obesity – options, effectiveness and perspectives
- Genetics of monogenic forms of diabetes
- Modern technologies in diabetology. CSII (Continuous Subcutaneous Insulin Infusion) and CGM (Continuous Glucose Monitoring) in clinical practice